Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene \textit{BRD3} is associated with poorer survival outcome in NSCLC

Jang Hyuck Lee\textsuperscript{1,2}, Seung Soo Yoo\textsuperscript{3}, Mi Jeong Hong\textsuperscript{1,2}, Jin Eun Choi\textsuperscript{1,2}, Hyo-Gyoung Kang\textsuperscript{1,2}, Sook Kyung Do\textsuperscript{1,2}, Won Kee Lee\textsuperscript{4}, Sun Ha Choi\textsuperscript{3}, Yong Hoon Lee\textsuperscript{3}, Hyewon Seo\textsuperscript{3}, Jaehee Lee\textsuperscript{3}, Shin Yup Lee\textsuperscript{3}, Seung Ick Cha\textsuperscript{3}, Chang Ho Kim\textsuperscript{3}, Eung Bae Lee\textsuperscript{5}, Sukki Cho\textsuperscript{6}, Sanghoon Jheon\textsuperscript{6} and Jae Yong Park\textsuperscript{1,2,3,7}

\textsuperscript{1} Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Korea
\textsuperscript{2} Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea
\textsuperscript{3} Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
\textsuperscript{4} Biostatistics, Medical Research Collaboration Center, Kyungpook National University, Daegu, Korea
\textsuperscript{5} Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea
\textsuperscript{6} Department of Thoracic and Cardiovascular Surgery, School of Medicine, Seoul National University, Korea
\textsuperscript{7} BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Korea

Keywords
BET genes; epigenetics; lung cancer; polymorphisms; prognosis

Correspondence
M. J. Hong, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, 680 gukchaebosang-ro, Jung-gu, Daegu 41944, Korea
Fax: +82 53 289 1466
Tel: +82 53 420 4868
E-mail: mcmx0530@naver.com
and
J. Y. Park, Departments of Internal Medicine, School of Medicine, Kyungpook National University Chilgok Hospital, 807, Hoguk-ro, Buk-gu, Daegu 41404, Korea
Fax: +82 53 200 2027
Tel: +82 53 200 2631
E-mail: jaeyong@knu.ac.kr

Jang Hyuck Lee and Seung Soo Yoo contributed equally to this paper

(B)romodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression. We investigated whether variants in BET genes are associated with survival outcomes for lung cancer. To do this, the associations between 77 variants in BET family genes and survival outcomes were analyzed in 773 non-small-cell lung cancer (NSCLC) patients who underwent surgery (349 and 424 patients in the discovery and validation cohorts, respectively). We found that six variants were significantly associated with overall survival (OS) in the discovery cohort, and one variant (rs2506711C>T) was replicated in the validation cohort. \textit{BRD3} rs2506711C>T is located in the repressed area and has a strong linkage disequilibrium with rs2427964C>T in the promoter region. \textit{BRD3} rs2427964C>T was significantly associated with worse OS in the discovery cohort, validation cohort, and combined analysis. In a luciferase assay, promoter activity in the \textit{BRD3} rs2427964 T allele was significantly higher than that in the \textit{BRD3} rs2427964 C allele, which selectively bound with the transcriptional repressor SIN3A. Knockdown of \textit{BRD3} with \textit{BRD3}-specific siRNA decreased the proliferation and migration of lung cancer cells while also increasing the rate of apoptosis. These results suggest that \textit{BRD3} rs2427964C>T increases \textit{BRD3} expression through increased promoter activity, which is associated with poor prognosis for lung cancer.

Abbreviations
aHR, adjusted hazard ratio; BET, bromodomain and extraterminal domain; BRD, bromodomain; CIs, confidence intervals; CTCF, CCCTC-binding factor; LD, linkage disequilibrium; MAF, minor allele frequency; NSCLC, non-small-cell lung cancer; OS, overall survival; rSNP, regulatory single nucleotide polymorphisms.
1. Introduction

Although cancer is generally considered a genetic disease, epigenetic aberration also plays an important role in carcinogenesis [1]. DNA methylation, histone modification, and microRNA gene silencing are examples of epigenetic modifications that can alter gene expression without changing nucleotide sequences. Recent studies have shown that epigenetic abnormalities are commonly found in human cancers and are involved in almost all stages of cancer development [1,2]. For example, histone modifications, such as methylation, phosphorylation, and acetylation, are necessary for gene expression. Aberrations in histone modification are associated with carcinogenesis or the prognosis of several cancer types including lung cancer [3,4]. Barlési et al. [5] found that epigenetic changes in histone modifications were significantly associated with disease-free and overall survival (OS) of resected non-small-cell lung cancer (NSCLC). In addition, Van Den Broeck et al. [6] reported that the loss of histone H4K20 trimethylation influenced NSCLC prognosis.

Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation; they occur on average almost once every 1000 nucleotides. Most SNPs do not affect health or disease, but a small number of have a significant impact on disease development or prognosis. In particular, when a SNP occurs in a regulatory region within or near a gene, it may affect the function of the gene, which increases the likelihood of affecting disease. Regulatory single nucleotide polymorphisms (rSNPs) are variants of transcription factor binding sites within gene promoter regions or enhancers; rSNPs are known to alter gene expression and affect human disease [7,8].

In the histone modification pathway, bromodomain and extraterminal domain (BET) proteins serve as epigenetic readers that regulate gene expression by recruiting chromatin-regulating enzymes of histone modification [9]. The BET family of proteins is composed of bromodomain-containing (BRD)2, BRD3, BRD4, and bromodomain testis-specific protein [10]. Dysregulation of BET family genes has been reported in cancers [11–13]. BET inhibitors targeting BET proteins have also been investigated; the BET inhibitors JQ1 and I-BET151 are known to suppress the growth of NSCLC [14], with JQ1 also having an effect on Kras-mutant NSCLC [15]. Given the roles played by BET family, variants of BET family genes could potentially influence the survival outcome of cancer patients. Therefore, in the present study, we investigated the effects of rSNPs of BET family genes on the survival outcome of patients with surgically resected NSCLC.

2. Materials and methods

2.1. Study population

This study was conducted in two stages. In the discovery cohort, we enrolled 349 NSCLC patients who underwent curative surgical resection at the Kyungpook National University Hospital between September 1998 and December 2007. In the validation cohort, we included 424 patients who underwent curative surgery for NSCLC at the Seoul National University Bundang Hospital between September 2005 and March 2012. All of these patients were Korean. Written consent and clinical samples were obtained prior to surgery, and the study was approved by the institutional review boards of both hospitals. Research was performed in accordance with the Declaration of Helsinki of the World Medical Association.

2.2. Polymorphism selection and genotyping

To collect polymorphisms, we used the rSNPBase database (http://rsnp.psych.ac.cn/result), which provides a curated human SNP resource with which to analyze the regulatory functions of all SNPs in the human genome and contains references to the regulatory elements with supporting experimental evidence [16]. We retrieved polymorphisms targeting the BRD2, BRD3, and BRD4 genes via the “List search” module in rSNPBase. The gene for bromodomain testis-specific protein was excluded from this study because it is a testis-specific chromatin protein. In total, 5669, 2025, and 2624 polymorphisms of BRD2, BRD3, and BRD4, respectively, were selected. We excluded SNPs with minor allele frequencies < 0.1 in HapMap JPT and those in strong linkage disequilibrium (LD) ($r^2 > 0.8$) using the TagSNP utility for LD-tag SNP selection in the SNPinfo web server (https://snpinfo.niehs.nih.gov/). Ultimately, 77 SNPs (59 in BRD2, 7 in BRD3, and 11 in BRD4) were selected. These polymorphisms were genotyped using a Sequenom MassARRAY iPLEX assay (Sequenom, San Diego, CA, USA) according to the manufacturer’s instructions. BRD3 rs2427964C>T, which was in strong LD with BRD3 rs2506711C>T, was genotyped using a TaqMan assay (Thermo Fisher Scientific, Foster City, CA, USA).
2.3. Promoter-luciferase constructs and luciferase assay

To investigate whether the rs2427964C>T variant modulates the promoter activity of the gene, we conducted a luciferase assay. A791-bp fragment (from −390 to +400 based on rs2427964) that included rs2427964C>T was synthesized by PCR using genomic DNA from a donor carrying a heterozygote. The forward primer with the KpnI restriction site (5′-GGGTTACCGGTTCGGACCT TCCCTAGAGC-3′) and the reverse primer with the XhoI restriction site (5′-CCGCTCGAGAGTTCCCGTTTG AAATCGACC-3′) were used. The PCR products were cloned into the KpnI/XhoI site of the pGL3-basic vector (Promega, Madison, WA, USA), which resulted in pGL3-Basic-BRD3 constructs containing either rs2427964 C or T alleles. The correct sequences of all the clones were verified by genome sequencing. The H1299 and A549 lung cancer cell lines were transfected with the pRL-SV40 vector (Promega) and pGL3-basic vector using Effectene (Qiagen, Hilden, Germany). The cells were harvested 48 h after transfection, and then, lysates were prepared using the Dual-Luciferase Reporter Assay System (Promega). Luciferase activity was measured using a Synergy HT Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT, USA), and the results were normalized to pRL-SV40 Renilla luciferase activity.

2.4. Chromatin immunoprecipitation with quantitative PCR

Chromatin immunoprecipitation (ChIP) assays were performed using the Pierce Magnetic ChIP Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Cell lysates from H1299 and A549 were sonicated to reach an average length of 300 bp using Vibra-Cell Ultrasonic Liquid Processors (Sonics & Materials, Danbury, CT, USA). The DNA–protein complex was then reacted with SIN3A and ETS1 antibodies (Abcam, Cambridge, UK). ChIP DNA was analyzed by quantitative PCR (qPCR) using QuantiFast SYBR Green PCR Master Mix (Qiagen) in a LightCycler 480 (Roche Life Science, Penzberg, Germany). The following primers were used: BRD3 forward, 5′-CCCCGTATCATTTCTCAGACG-3′; BRD3 reverse, 5′-TTCTCCCGTTCGACCACAATCCT-3′.

2.5. Electrophoretic mobility shift assay and supershift assay

An electrophoretic mobility shift assay was performed using the LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Nuclear extracts were prepared from H1299 and A549 cells using Pierce NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Fisher Scientific). Complementary 31-bp oligonucleotides (based on rs2427964 from −15 to +15) were synthesized: 5′-CTGAGCAGGAGCTTCCCAAC CAAAATTAAG-3′ and 5′-CTGAGCGAAGCT TTCAACCAATTTAAG-3′ (the polymorphic alleles are indicated by bold letters). The DNA–protein complex bands were quantified by densitometry analysis using IMAGE-STUDIO 5.2 software (LI-COR, Lincoln, NE, USA). A supershift assay was performed using 10 μg of nuclear extract incubated with SIN3A and ETS1 antibodies before the labeled probe step.

2.6. The Cancer Genome Atlas data analysis

mRNA sequencing data on gene expression were obtained from The Cancer Genome Atlas (TCGA) through the Broad Institute’s fire browse data portal for TCGA squamous cell carcinoma and adenocarcinoma cohorts. In total, 51 lung squamous cell carcinoma and 58 lung adenocarcinoma tumor-paired normal tissue samples were included in our analysis.

2.7. Protein extraction and western blotting

H1299 and A549 cell lines were washed twice with pre-chilled phosphate-buffered saline (PBS) and then the appropriate amount of mammalian protein extraction reagent (Thermo Fisher Scientific) was added to the cells. Protein concentrations were determined with a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Total protein lysates were separated by SDS/PAGE on 10% SDS/acylamide gels. Subsequently, they were transferred to polyvinylidene difluoride membranes (Merck, Darmstadt, Germany) and then incubated in blocking buffer. BRD3 (Abcam) was used as a primary antibody, whereas β-actin (primary antibody; Santa Cruz Biotech, Santa Cruz, CA, USA) was used as an internal control. Immunoreactive proteins were visualized using Immobilon Western Chemiluminescent HRP Substrate (Merck).

2.8. BRD3 small interfering RNAs and transfection

BRD3 knockdown in human lung cancer cells was achieved by the transfection of BRD3 small interfering RNA (siRNA), denoted siBRD3, which was synthesized by Bioneer (Daejeon, Korea). The siRNA sequence targeting BRD3 corresponded to the coding regions (5′-CUAGAGUCCGCUAGUUU-3′;
antisense 5'-AACAUCAGCCGGACAUCA-3') of the BRD3 gene. A nonspecific siRNA oligonucleotide from Bioneer was used as a negative control (siCtrl), whereas untreated cells or cells treated only with transfection reagents were used as controls (Mock). Cells in the exponential phase of growth were plated. After 24 h, cells were transfected with 100 nm of siRNA using Effectene transfection reagent (Qiagen) according to the manufacturer’s protocol.

2.9. Cell proliferation assay

*In vitro* cell proliferation was tested using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. First, cells were seeded at a density of 4 × 10^3 cells per well in 96-well culture plates. After 24 h, the medium was removed and the cells were transfected with siBRD (Bioneer) using Effectene (Qiagen). Cell viability was then determined at different time points using a Multiskan FC Microplate Photometer (Thermo Fisher Scientific). The cell viability in each well was measured in terms of optical density at a wavelength of 570 nm.

2.10. Transwell invasion assay

Cell invasion assays were performed using BioCoat Matrigel invasion chambers (24-well; 8-µm pore size; Corning, NY, USA). Before the experiment, Matrigel-coated Transwell inserts were rehydrated in 500 µL of serum-free RPMI-1640 medium and incubated at 37 °C for 2 h. First, H1299 and A549 cells were trypsinized and washed with PBS; subsequently, 2.5 × 10^4 cells were suspended in 500 µL of RPMI-1640 without fetal bovine serum and the suspension was added to the upper chamber, whereas 750 µL of RPMI-1640 containing 10% fetal bovine serum was added to the lower chamber. The cells were allowed to invade for 12 h, after which they were fixed with 3.7% paraformaldehyde for 20 min, washed with PBS, and then stained with 0.05% crystal violet in 20% methanol for 30 min. The Transwell inserts were washed with PBS and the noninvasive cells in the upper chambers were removed with cotton swabs. Representative images were acquired using an inverted microscope (Nikon, Tokyo, Japan), and the percentage of stained cells was measured using an image analyzer (IMAGE-StUDIO 5.2).

2.11. Wound-healing assay

H1299 and A549 cells were seeded in separate 6-well plates and allowed to grow until confluence. The confluent monolayers of these cells were gently scratched using sterile 20-µL pipette tips before being rinsed with PBS to remove cellular debris. Cells were then treated with the previously indicated concentrations of siRNA, after which the 6-well plates were incubated at 37 °C in 5% CO₂ for 0, 24, and 48 h. For each time point, the scratched area was then observed and photographed under an inverted microscope, and the distance of the scratch closure was examined. Wound closure was measured using the MRI wound-healing tool plugin for ImageJ (https://github.com/MontpellierRessourcesImagerie/imagej_macros_and_scripts/wiki/Wound-Healing-Tool). To generate a wound closure percentage, measurements were normalized to the initial scratch area (0 h measurement = 100%) for each replicate.

2.12. Cell apoptosis analysis with an annexin V assay

H1299 and A549 cells transfected with siBRD3 or scrambled siRNA were gently dissociated with trypsin/EDTA and stained for annexin V and propidium iodide using the Annexin V-FITC Apoptosis Detection Kit (Abcam) according to manufacturer's instructions. The stained cells were immediately analyzed with a BD FACS Calibur system (BD Biosciences, Heidelberg, Germany).

2.13. Statistical analyses

The OS data were analyzed with the Kaplan–Meier method. The OS was calculated from the day of surgery to the day of death or the last follow-up. Adjusted hazard ratio (aHR) and 95% confidence intervals (CIs) were calculated for multivariate statistical models (Cox proportional hazards models) with adjustments for age, gender, smoking status, pathologic stage, and adjuvant therapy. P < 0.05 was considered statistically significant. All analyses were performed using Statistical Analysis System for Windows, version 9.4 (SAS Institute, Cary, NC, USA).

3. Results

3.1. Associations between polymorphisms and survival outcomes

The characteristics of the patients and the associations with OS are shown in Table S1. Pathologic stage had a statistically significant effect on OS in both cohort groups. Younger age was associated with better OS in
the discovery cohort; female, never smoking, and adenocarcinoma were associated with better OS in the validation cohort (Table S1).

Of the 77 SNPs genotyped, 59 were analyzed after excluding 18 SNPs with genotype failure or deviations from Hardy–Weinberg equilibrium (Table S2). In the discovery cohort, six SNPs were significantly associated with OS (P < 0.05) (Table S3). Among these six SNPs, only BRD3 rs2506711C>T was replicated with the same direction as the discovery cohort in the validation cohort. BRD3 rs2506711C>T was significantly associated with worse OS in the discovery cohort, validation cohort, and combined analysis (under a recessive model; aHR = 1.79, 95% CIs = 1.17–2.74, P = 0.01; aHR = 1.97, 95% CIs = 1.18–3.28, P = 0.01; and aHR = 1.91, 95% CIs = 1.38–2.65, P = 9 × 10−5, respectively; Table 1).

According to annotations including histone modification signals, DNase, and transcription factor binding sites in ChIP-seq data from the ENCODE project, rs2506711C>T is located in heterochromatin and the repressed area (Fig. 1A and S3). Therefore, the effect of rs2506711C>T on OS may be due to other causal SNPs in LD. Although rs2506711C>T is a tag variant, four different SNPs are in a strong LD relationship (D’ = 0.99 and r² ≥ 0.98) with rs2506711 (Fig. 1B,C). The functional annotations of five SNPs in LD are shown in Fig. 1 and Table S4. Among these five LD SNPs, BRD3 rs2427964 is located in a potential regulatory region, including various transcription factor binding sites (combined with multiple cell lines), with high chromatin accessibility as measured by DNase1 hypersensitivity, and a strong signal for an active histone marker (H3K4Me3 and H3K27Ac). BRD3 rs2427964 has strong LD with rs2506711 (D’ = 0.99 and r² = 0.98), is located in the transcription factor binding region, and is predicted to act as a promoter (Table S4). BRD3 rs2427964C>T was also associated with worse OS in the discovery cohort, validation cohort, and combined analysis (under a recessive model; aHR = 1.70, 95% CIs = 1.11–2.61, P = 0.02; aHR = 1.97, 95% CIs = 1.18–3.28, P = 0.01; and aHR = 1.92, 95% CIs = 1.39–2.65, P = 8 × 10−5, respectively; Table 1 and Fig. 2).

In stratified analysis, the effect of BRD3 rs2427964 on survival outcomes differed according to histological cell type (Table S5). Significant associations between BRD3 rs2427964 and worse OS were found in adenocarcinoma (aHR = 2.78, 95% CIs = 1.77–4.35, P = 8 × 10−5) but not in squamous cell carcinoma (aHR = 1.35, 95% CIs = 0.81–2.25, P = 0.25; P < 0.05 for the homogeneity test; Table S5).

**Table 1.** OS according to genotypes of the rs2506711C>T and rs2427964C>T in the discovery, validation, and combined cohorts. MAF, minor allele frequency; no, number.

| Polymorphism target gene | Genotypes | Discovery cohort | Validation cohort | Combined analysis |
|--------------------------|-----------|-----------------|------------------|------------------|
|                         | no        | MAF | aHR (95% CIs) | P       | no        | MAF | aHR (95% CIs) | P       | no        | MAF | aHR (95% CIs) | P       |
| rs2506711a               | CC        | 113 | 0.44 1.00     | 0.69   | 238 0.44 1.00 | 0.83  | 592 0.44 1.00 | 0.68  |
|                         | CT        | 163 | 1.12 (0.70–1.78) | 0.22  | 222 1.00 (0.59–1.69) | 0.99  | 445 1.00 (0.58–1.67) | 0.99  |
|                         | TT        | 72  | 1.33 (1.15–3.21) | 0.01  | 73 1.45 (0.90–2.36) | 0.36  | 146 1.50 (0.94–2.40) | 0.17  |
|                         | Dominant  | 226 | 1.39 (1.17–5.24) | 0.01  | 295 1.04 (0.66–1.64) | 0.92  | 521 1.04 (0.67–1.62) | 0.90  |
|                         | Recessive | 226 | 1.39 (1.17–5.24) | 0.01  | 295 1.04 (0.66–1.64) | 0.92  | 521 1.04 (0.67–1.62) | 0.90  |
|                         | Codominant| 1.33 (1.06–1.69) | 0.42  | 1.39 (1.01–1.94) | 0.10  | 1.39 (1.01–1.94) | 0.10  |
| rs2427964a              | CC        | 115 | 0.44 1.00     | 0.69   | 238 0.44 1.00 | 0.83  | 592 0.44 1.00 | 0.68  |
|                         | CT        | 163 | 1.12 (0.70–1.78) | 0.22  | 222 1.00 (0.59–1.69) | 0.99  | 445 1.00 (0.58–1.67) | 0.99  |
|                         | TT        | 72  | 1.33 (1.15–3.21) | 0.01  | 73 1.45 (0.90–2.36) | 0.36  | 146 1.50 (0.94–2.40) | 0.17  |
|                         | Dominant  | 226 | 1.39 (1.17–5.24) | 0.01  | 295 1.04 (0.66–1.64) | 0.92  | 521 1.04 (0.67–1.62) | 0.90  |
|                         | Recessive | 226 | 1.39 (1.17–5.24) | 0.01  | 295 1.04 (0.66–1.64) | 0.92  | 521 1.04 (0.67–1.62) | 0.90  |
|                         | Codominant| 1.33 (1.06–1.69) | 0.42  | 1.39 (1.01–1.94) | 0.10  | 1.39 (1.01–1.94) | 0.10  |

P-values were calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, tumor histology, pathological stage, and adjuvant therapy.
3.2. Effect of BRD3 rs2427964 on promoter and transcription activity

The variant rs2427964C>T is estimated to be a promoter region of BRD3; thus, the effect of rs2427964C>T on BRD3 promoter activity was assessed in vitro using a luciferase assay. Promoter activity was significantly increased with the rs2427964 T allele relative to with the rs2427964 C allele in both H1299 and A549 cell lines (Fig. 3A).

Using publicly available ChIP-seq data from the ENCODE database, we searched several transcription factors binding to the BRD3 promoter region.
factors that were identified to bind over rs2427964. According to the transcription factor ChIP-seq data set of A549 cells, rs2427964 is located in SIN3A and ETS1 binding regions (Fig. 1A). In this study, we confirmed that the rs2427964-containing region was in SIN3A and ETS1 binding regions not only in the A549 cell line but also in the H1299 cell line. The input ratio using ChiP-qPCR was higher in the rs2427964-containing region compared with that in the control (IgG) in both H1299 and A549 cell lines (Fig. 3B).

An electrophoretic mobility shift assay was performed to determine differences in binding to transcription factors according to the rs2427964 alleles. As shown in Fig. 3C, the rs2427964 C allele (lane 2) bound more transcription factors than were bound with the rs2427564 T allele (lane 7). The density of shift of a biotin-labeled T allele probe was reduced with a competitor C allele (lane 10) compare with the effect observed with a competitor T allele (lane 8). In contrast, the density of shift of a biotin-labeled C allele probe was increased with a competitor T allele (lane 5) relative to the effect with a competitor C allele (lane 3). The transcription factors SIN3A and ETS1 are known to bind to rs2427964. To assess whether the degree of binding to SIN3A and ETS1 differed

Fig. 2. OS curves according to the BRD3 rs2427964 genotypes. The discovery cohort (A, B), validation cohort (C, D), and combined analysis (E, F). P values were calculated using a multivariate Cox proportional hazard model.
depending on the rs2427964 C or T alleles, we conducted a supershift assay. As shown in Fig. 3D, the EST1 antibody bound to both C and T alleles but the SIN3A antibody selectively bound to the C allele. Since SIN3A is known as a transcription repressor [17], the binding between the BRD3 rs2427964 C allele
and SIN3A is expected to reduce BRD3 expression. To determine whether SIN3A is functional in conjunction with BRD3, we conducted an experiment on siRNA-mediated knockdown of the SIN3A gene in H1299 and A549 cell lines. We confirmed via RT-PCR and western blot that the expression of BRD3 mRNA and protein increased when SIN3A expression was reduced using siRNA (Fig. S1A,B).

### 3.3. BRD3 expression in cancer cell lines and effects on survival

To explore the potential role of BRD3, we first examined BRD3 mRNA expression in cancer cell lines. Cancer cell encyclopedia data showed that BRD3 mRNA expression levels were elevated in various human cancer cell lines including lung cancer (Fig. S2A). Thus, we measured BRD3 mRNA expression in various lung cancer cell lines using RT-PCR and found that expression was elevated in several cell lines (Fig. S2B). In addition, TCGA data showed that BRD3 mRNA expression was significantly higher in lung cancers than the expression in adjacent normal tissues (Fig. 4A). Moreover, OS was worse in patients showing high BRD3 expression compared with OS in those showing low BRD3 expression ($P = 0.048$, Fig. 4B).

### 3.4. Effects of BRD3 silencing on cancer cells

To evaluate the knockdown efficacy of BRD3, we used three commercial siRNAs. After transfection with

---

**Fig. 4.** BRD3 expression and survival data obtained from The Cancer Genome Atlas (TCGA) database. (A) The mRNA expression level of BRD3 in tumor and normal lung tissues as determined via TCGA database. The mRNA expression level was obtained from 109 lung cancer patients (61 with lung squamous cell carcinoma and 58 with lung adenocarcinoma). $*P < 0.05$. (B) Kaplan–Meier plots of OS according to BRD3 mRNA expression determined via TCGA database. High- and low-expression groups were defined by the median BRD3 mRNA expression value of the tumor tissues.
siBRD3, the level of BRD3 mRNA expression decreased significantly compared with levels in the control (Fig. S1C). Western blots showed that BRD3 expression was significantly reduced in H1299 and A549 cells after transfection with siBRD3 (Fig. S1D). Since BRD3 is highly expressed in lung cancer, we tested whether BRD3 knockdown affected lung cancer cell proliferation. As shown in Fig. 5A, when siBRD3 was transfected, cell proliferation was significantly reduced in both H1299 and A549 cell lines.

The effect of BRD3 knockdown on cell invasion ability was investigated using a Transwell invasion assay after transfection with siBRD3. H1299 and A549 cell invasion was significantly repressed in the siBRD3 group compared with cell invasion in the Mock and siCtrl groups (Fig. 5B). A wound-healing assay also showed that cell migration was reduced after transfection with siBRD3 for 48 h (Fig. 5C).

Annexin V-FITC double staining and flow cytometry analysis were performed to determine whether BRD3 silencing had an effect on cell apoptosis. In BRD3-silenced H1299 and A549 cells, the percentage of apoptotic cells increased in comparison with the percentage in the control group (Fig. 6A,B).

4. Discussion

As epigenetic readers, BET proteins are critical regulators of transcription. Bromodomain proteins bind to acetylated histone lysine residues and mediate downstream functions such as histone acetylation, chromatin remodeling, and transcriptional regulation [18]. BET proteins are also involved in cancer pathogenesis or progression through promotion of aberrant oncogene expression [9]. For example, BRD4 regulates breast cancer dissemination through Jagged1/Notch1 signaling [19]. The proto-oncogene MYC is also associated with BET proteins; BET inhibitor downregulates MYC transcription leading to therapeutic effects on multiple myeloma and medulloblastoma [20,21].
In the present study, BRD3 rs2427964C>T was associated with worse OS in both the discovery and validation cohorts. BRD3 plays a role in the regulation of transcription, probably through chromatin remodeling and interactions with transcription factors [22]. Although the BRD3-NUT fusion gene has been reported in NUT midline carcinoma, the role of BRD3 in cancers is not well known. According to TCGA data, BRD3 expression was higher in lung cancer tissues than it was in tumor-paired normal tissue. Moreover, OS was worse in patients with high BRD3 expression. Following knockdown of BRD3 with BRD3-specific siRNA, we found that the growth of lung cancer cells (H1299 and A549) decreased over time. Cell invasion and migration were also inhibited after transfection with siBRD3. Taken together, these results suggest that BRD3 plays important roles in cancer cell growth and migration. Furthermore, we found that BRD3 silencing increased the apoptosis rate in lung cancer cells compared with the rate observed in the control. Therefore, in a similar manner to BRD4-targeting inhibitors suppressing NSCLC growth [14], drugs targeting BRD3 could potentially treat lung cancer.

Our genotype analysis showed that patients with the rs2427964TT genotype had worse survival outcomes than those with the rs2427964CC/CT genotype. This result is biologically plausible because (a) TCGA data showed that patients with high BRD3 expression had worse prognosis than those with low BRD3 expression and (b) BRD3 silencing decreased the proliferation and migration of cancer cells. Thus, a lack of BRD3 expression or at least low expression seems to improve prognosis. We also showed that the rs2427964 T allele had higher promoter activity than that of the rs2427964 C allele. There is a possibility, according to our findings, that differences in binding to the transcriptional repressor SIN3A related to the rs2427964 allele could be associated with differences in BRD3 expression. In summary, BRD3 rs2427964C>T may increase BRD3 expression through an increase in promoter activity; this likely leads to poor prognosis for lung cancer patients. In additional analysis, BRD3 expression showed a tendency to increase in the rs2427964 T allele in 124 lung cancer tissues, but this trend was not statistically significant (data not shown).

Unlike BRD2 or BRD4, the functional role of BRD3 in carcinogenesis is not currently clear. A recent study showed that BRD2 and BRD3 are colocalized with the architectural/insulator protein CCCTC-binding factor (CTCF), which serves to increase the boundary function of CTCF [23]. The same study suggested that BRD2 or BRD3 defects could lead to improper coregulation of genes that normally remain isolated as well as increasing ectopic interactions across domain boundaries [23]. BET inhibitors preferentially suppress the transcription of cancer-promoting genes and show clinical effects in several human cancers [10,13,14]. As mentioned earlier, BRD3 may affect cancer prognosis by controlling the expression of oncogenes, such as MYC, in a similar manner to BRD4. Nevertheless, further research is required to determine whether the BRD3 abnormalities themselves affect cancer prognosis or whether they affect cancer prognosis through the interactions of other epigenetic modulators and/or oncogenes.

5. Conclusion
In summary, the BRD3 rs2427964C>T allele was associated with survival outcomes for surgically resected NSCLC patients. The patients with the rs2427964TT genotype had worse survival outcomes than those with the rs2427964CC or CT genotype. Specifically, the rs2427964 C allele was selectively bound with a transcriptional repressor and showed lower promoter activity. Additionally, BRD3 mRNA expression was higher in lung cancers than the expression in normal tissues and patients with high BRD3 expression had worse OS. We also found that BRD3 silencing decreased the proliferation and migration of cancer cells. These results suggest that worse survival outcome in NSCLC may be related to an increase in BRD3 expression associated with the change of BRD3 rs2427964C to rs2427964T.

Acknowledgements
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2020R1A5A2017323). The research was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R111A3A01041319).

Conflict of interest
The authors declare no conflict of interest.

Peer Review
The peer review history for this article is available at https://publons.com/publon/10.1002/1878-0261.13109.

Data accessibility
The datasets and materials in this study are available on reasonable request from corresponding authors or first author.
Author contributions
JHL., SSY, MJH, and JYP conceived and designed the study; SSY, SHC, YHL, HWS, JHL, SYL, SIC, CHK, SKC, SHJ, and JYP contributed provision of study material or patients; JHL, SSY, MJH, JEC, HGK, SKD, SHC, YHL, and HWS collected the data; JHL, SSY, MJH, JEC, WKL, SYL, SIC, CHK, and JYP analyzed and interpreted the data; and JHL, SSY, MJH, and JYP wrote the manuscript.

References
1 Flavahan WA, Gaskell E & Bernstein BE (2017) Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380.
2 Jones PA & Baylin SB (2007) The epigenomics of cancer. Cell 128, 683–692.
3 Kurdistani SK (2011) Histone modifications in cancer biology and prognosis. Prog Drug Res 67, 91–106.
4 Chervona Y & Costa M (2012) Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res 2, 589–597.
5 Barlési F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA & Rodriguez JA (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25, 4358–4364.
6 Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B & Gazzeri S (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14, 7237–7245.
7 Harak Singh RR & Snyder MP (2013) Impacts of variation in the human genome on gene regulation. J Mol Biol 425, 3970–3977.
8 Kasowski M, Grubert F, Heffelfinger C, Hariharan M, Asabere A, Waszak SM, Waszak HL, Rozowsky J, Shi M, Urban AE et al. (2010) Variation in transcription factor binding among humans. Science 328, 232–235.
9 Stathis A & Bertoni F (2018) BET proteins as targets for anticancer treatment. Cancer Discov 8, 24–36.
10 Xu Y & Yakov CR (2017) Targeting Cancer Cells with BET Bromodomain Inhibitors. Cold Spring Harb Perspect Med 7, a026674.
11 Donati B, Lorenzini E & Ciarrocchi A (2018) BRD4 and cancer: going beyond transcriptional regulation. Mol Cancer 17, 164.
12 Lu L, Chen Z, Lin X, Tian L, Su Q, An P, Li W, Wu Y, Du J, Shan H et al. (2020) Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail. Cell Death Differ 27, 255–268.
13 White ME, Fenger JM & Carson WE 3rd (2019) Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cell Immunol 337, 48–53.
14 Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P, Cheng Z & Wang X (2018) Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Cancer Biol Ther 19, 407–415.
15 Shimamura T, Chen Z, Souchetay M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J et al. (2013) Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 19, 6183–6192.
16 Guo L, Du Y, Chang S, Zhang K & Wang J (2014) rSNPBase: a database for curated regulatory SNPs. Nucleic Acids Res 42, D1033–D1039.
17 Ellison-Zelski SJ & Alarid ET (2010) Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor. Mol Cancer 9, 263.
18 Pfister SX & Ashworth A (2017) Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov 16, 241–263.
19 Andrieu G, Tran AH, Strissel KJ & Denis GV (2016) BRD4 regulates breast cancer dissemination through jagged1/Notch1 signaling. Cancer Res 76, 6555–6567.
20 Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917.
21 Bandopadhyay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin YS, Schumacher SE, Zeid R, Masoud S et al. (2014) BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 209, 12–25.
22 LeRoy G, Rickards B & Flint SJ (2008) The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 30, 51–60.
23 Hsu SC, Gilgenast TG, Bartman CR, Edwards CR, Stonestrom AJ, Huang P, Emerson DJ, Evans P, Werner MT, Keller CA et al. (2017) The BET protein BRD2 cooperates with CTCF to enforce transcriptional and architectural boundaries. Mol Cell 66, 102–116.e7.
24 ENCODE Project Consortium, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shores N, Adrian J, Kawli T, Davis CA, Dobin A et al. (2020) Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583, 699–710.

Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article.
**Fig. S1.** Effects of SIN3A knockdown on BRD3 mRNA and protein expression. (A) RT-PCR analysis ($n = 4$) of SIN3A mRNA knockdown via 100-nM siRNA in H1299 and A549 cells, and BRD3 mRNA expression after knockdown of SIN3A. Columns: means of independent experiments; bars: standard deviations. $P$ values are derived from comparisons with the Mock control group by $t$-test: $*P < 0.001$. (B) BRD3 protein expression, according to western blots, after transfection with siSIN3A; $\beta$-actin was used as an internal control. (C) RT-PCR analysis ($n = 4$) of BRD3 mRNA knockdown by 100-nM siRNA in A549 cells. BRD3 mRNA expression decreased after transfection with three commercial BRD3 siRNAs (siBRD3) compared with expression in the control. $P$ values are derived from comparisons with the Mock control group by $t$-test: $*P < 0.01$. (D) The expression of BRD3 protein after transfection with siBRD3 by western blots; $\beta$-actin was used as an internal control.

**Fig. S2.** Expression of BRD3 in cancer cell lines. (A) Box plots showing RNA-seq data of mRNA expression from the Cancer Cell Line Encyclopedia: dashed lines within a box represent the mean. Cell lines from the same area or system of the body are grouped together; lineages are indicated at the bottom of the graph; the number of cell lines is shown in parenthesis. (B) Expression of BRD3 in various lung cancer cell lines according to RT-PCR analysis. MRC5 cell line: human lung fetal fibroblast cells.

**Fig. S3.** Definition of track colors of chromHMM tracks from the Roadmap Consortium. This track displays the chromatin state segmentation for the cell types used by the Roadmap Consortium. In total, 15 states (Primary), 18 states (Auxiliary), and 25 states (Imputed) were used to segment the genome; these states were then grouped and colored to highlight the predicted functional elements.

**Table S1.** Univariate analysis for OS by clinicopathologic features in the discovery and validation cohorts.

**Table S2.** Summary of studied polymorphisms.

**Table S3.** Six polymorphisms associated with OS in the discovery cohorts with $P < 0.05$ and their validation.

**Table S4.** Summary of the functional annotation for five polymorphisms within LD.

**Table S5.** Stratified analysis of the effects of rs2427964C>T genotypes under a recessive model on survival outcomes.